July 2 (Reuters) - AstraZeneca has entered into a deal worth up to $1.77 billion with CSPC Pharmaceutical Group to discover ...

Abbisko will lead the study, with both companies jointly sharing clinical trial responsibilities.

Texas Attorney General Ken Paxton announced Monday that his office has reached a settlement with AstraZeneca Pharmaceuticals ...

Abbisko Therapeutics Co. Ltd. on Wednesday entered into a strategic collaboration with AstraZeneca Plc AZN to jointly develop ...

AstraZeneca (LSE:AZN) secured European Union approval for Enhertu as the first HER2-directed antibody drug conjugate with a ...

AstraZeneca will pay $34 million to resolve a lawsuit that alleged the company used illegal kickbacks to induce providers to ...

AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical, paying the Chinese biotech $30 million upfront to jointly discover and develop two kidney disease drug ...

AstraZeneca has impressed oncology patient groups, rising to second place on PatientView’s corporate reputation ranking on the back of strength in breast and lung cancer. | AstraZeneca has impressed ...

AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout the research process.

AstraZeneca (LSE:AZN) is back in focus after a recent pullback, with the stock down about 5% over the past month and over the past 3 months, prompting investors to reassess its current valuation. See ...

The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a ...

Abbisko Therapeutics Co., Ltd. ('Abbisko Therapeutics' hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) ...